,108 Blinatumomab (anti-CD3, CD19), a BiTE approved by the FDA in 2014 for treatment of relapsed and refractory precursor B cell acute lymphoid leukemia (ALL), was placed in a randomized phase III trial with chemotherapeutic agents to demonstrate its in vivo efficacy and tolerability against CD19-positive ALL in 2019. Here, CD19 is linked to acute lymphoblastic leukemia.